Chitotriosidase and soluble IL-2 receptor: Comparison of two markers of sarcoidosis severity

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 6, 2008, Pages 479-483

  Bargagli, Elena ^a,b   Bianchi, Nicola ^a   Margollicci, Maria ^a   Olivieri, Carmela ^a   Luddi, Alice ^a   Coviello, Giuseppe ^b   Grosso, Salvatore ^a   Rottoli, Paola ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Chitotriosidase; Markers; Sarcoidosis; Serum; Soluble IL 2 receptor

Indexed keywords

CHITOTRIOSIDASE; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIODIAGNOSIS; RADIOGRAPHY; SARCOIDOSIS;

BIOLOGICAL MARKERS; FEMALE; HEALTH; HEXOSAMINIDASES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; SARCOIDOSIS; SMOKING; SOLUBILITY;

EID: 52949119128     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701854975     Document Type: Article

References (40)

1. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-18.
2. Rottoli P, Bargagli E. Is bronchoalveolar lavage obsolete in the diagnosis of interstitial lung disease? Curr Opin Pulm Med 2003;9:418-25.
3. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:204-11.
4. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. BAL and sierological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003;21:407-13.
5. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:1423-30.
6. Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in BAL fluid is highly variable. Eur Respir J 1997;10:2716-21.
7. Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996;157:910-18.
8. Straub JP, van Kamp GJ, van Maarsseveen TC, Stam J. Biochemical parameters in BAL of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1995;12:51-7.
9. Lieberman J. Elevation of serum angiotensin-converting enzyme (ACE) level in sarcoidosis. Am J Med 1975;59:365.
10. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis 1999;16:24-31.
11. Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance: a review. J Clin Pathol 1983;36:938-47.
12. Lieberman J, Schleissner LA, Nosal A, Sastre A, et al. Clinical correlations of serum angiotensin-converting enzyme in sarcoidosis. A longitudinal study of serum ACE, 67 Gallium scans, chest roentgenograms and pulmonary function. Chest 1983;84:522-8.
13. Costabel U. Biochemistry. Sarcoidosis, 438-9.
14. Sharma P, Smith I, Maguire G, et al. Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 1997;349:1602-3.
15. Gronhagen-Riska C, Kuppa K, Fyhrquist F, et al. Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis. Scand J Respir Dis 1978;59:228-31.
16. Thomas AV, Ansari A, Khurana M, et al. Elevated serum angiotensin-converting enzyme in miliary tuberculosis. Am Rev Respir Dis 1979;119:83.
17. Lieberman J, Beutler E. Elevation of serum angiotensin-converting enzyme in Gaucher's disease. N Engl J Med 1976;294:1442-4.
18. Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med 1980;93:825-6.
19. Smallridge RC, Rogers J, Verma PS. Serum angiotensin-converting enzyme: alterations in hyperthyroidism, hypothyroidism and subacute thyroiditis. J Am Med Assoc 1983;250:2489-93.
20. Ziegenhagen MW, Rothe ME, Schlaak M, Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003;21:407-13.
21. Rothkrantz-Kos S, Van Dieijen-Visser MP, Mulder PGH, Drent M. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003;49:1510-17.
22. Grutters JC, Fellrath JM, Mulder L, Janssen R, et al. Serum soluble IL2 receptor measurement in patients with sarcoidosis. Chest 2003;124:186-95.
23. Grosso S, Margollicci MA, Bargagli E, et al. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest 2004;64:57-62.
24. Van Eijk M, Van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase: a component of innate immunity. Int Immunol 2005;15:1505-12.
25. Wajner A, Michelin K, Burin MG, et al. Biochemical characterisation of chitotriosidase enzyme. Comparison between normal individuals and patients with Gaucher and Niemann-Pick disease. Clin Biochem 2004;37:893-7.
26. Labadaridis I, Dimitriou E, Theodorakis M, et al. Chitotriosidase in neonates with fungal and bacterial infections. Arch Dis Child Fetal Neonatal Ed 2005;90:531-2.
27. Altarescu G, Rudensky B, Abrahamov A, et al. Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol 2003;72:285-6.
28. Aguilera B, Ghauharali-van der Vlugt K, Helmond MTJ, et al. Transglycosidase activity of chitotriosidase. J Biol Chem 2003;42:40911-16.
29. Bargagli E, Margollicci M, Perrone M, et al. Chitotriosidase levels in BAL of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. In press.
30. Bargagli E, Margollicci MA, Nikiforakis N, et al. Chitotriosidase levels in serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration. In press.
31. Bargagli E, Margollicci MA, Luddi A, et al. Chitotriosidase in BAL of patients with diffuse lung diseases. Resp Med. In press.
32. Bargagli E, Rottoli P. Serum chitotriosidase activity in sarcoidosis patients. Rheumatol Int 2007;27:1187.
33. Hunninghake WG, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 1999;160:736-55.
34. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. Br J Med 1961;2:1165-72.
35. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005;5:1423-30.
36. Malaguarnera L, Musumeci M, Di Rosa M, Scuto A, et al. Interferon-gamma, tumour necrosis factor-alpha and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. J Clin Lab Anal 2005;19:128-32.
37. Drent M, Costabel U. Sarcoidosis. European Respiratory Monograph 2005;10:13.
38. Sengpiel AL, Jaksztat E, Welker L, et al. Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2005;22:214-21.
39. Papakosta D, Kyriazis G, Gioulekas D, et al. Variations in alveolar cell populations, lymphocyte subsets and NK-cells in different stages of active pulmonary sarcoidosis. Sarcoidosis Vasc Diff Lung Dis 2005;22:21-6.
40. Baughman RP, Lower E, Bradley D, Raymond LA, et al. Etanercept for refractory ocular sarcoidosis. Chest 2005;128:1062-7.